Atherosclerosis, Insulin Resistance, Kidney Transplantation
Conditions
Keywords
Kidney Transplantation, Thiazolidinediones, Insulin Resistance, Atherosclerosis
Brief summary
The aim of this study was to evaluate the effect of pioglitazone treatment on insulin secretion, insulin resistance, and progression of atherosclerosis in renal allograft recipients without preoperative history of diabetes.
Detailed description
This is a prospective, randomized, open-label study. The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months. After treatment, we estimated insulin sensitivity index for transplantation,first phase and second phase insulin secretion, secretion area under the curve,and carotid intima-media thickness.
Interventions
DRUGPioglitazone
The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Renal allograft recipients were eligible to participate in the study if they were aged ≥ 18 years, had no previous history of organ transplantation and were not currently using steroids or other immunosuppressants.
Exclusion criteria
* Diabetes before transplantation * Severe metabolic or infectious disease * Hepatic disease * Congestive heart failure (New York Heart Association II-IV) * Cadaver donor kidney donor transplantation * Unstable condition of the transplanted kidney
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin Resistance and Insulin Secretion | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| carotid intima-media thickness | 1 year |
Countries
South Korea
Outcome results
None listed